Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.
Hoffmann-La Roche Ltd; and license agreement with Stanford University.
The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 12, 24 | -0.28 Increased by +37.78% | -0.51 Increased by +45.10% |
| Mar 21, 24 | -0.47 Increased by +11.32% | -0.48 Increased by +2.08% |
| Nov 9, 23 | -0.43 Increased by +25.86% | -0.50 Increased by +14.00% |
| Aug 7, 23 | -0.48 Increased by +21.31% | -0.49 Increased by +2.04% |
| May 11, 23 | -0.45 Increased by +29.69% | -0.51 Increased by +11.76% |
| Mar 29, 23 | -0.53 Increased by +27.40% | -0.60 Increased by +11.67% |
| Nov 10, 22 | -0.58 Increased by +7.94% | -0.56 Decreased by -3.57% |
| Aug 10, 22 | -0.61 Increased by +4.69% | -0.68 Increased by +10.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 2.09 M Increased by +48.05% | -17.90 M Increased by +5.55% | Decreased by -857.01% Increased by +36.20% |
| Sep 30, 23 | 2.53 M Increased by +19.70% | -16.26 M Increased by +23.21% | Decreased by -643.08% Increased by +35.85% |
| Jun 30, 23 | 1.43 M Increased by +2.87% | -18.06 M Increased by +18.91% | Decreased by -1.26 K% Increased by +21.18% |
| Mar 31, 23 | 1.83 M Increased by +124.60% | -15.54 M Increased by +33.79% | Decreased by -851.31% Increased by +70.52% |
| Dec 31, 22 | 1.41 M Increased by +177.76% | -18.95 M Increased by +30.21% | Decreased by -1.34 K% Increased by +74.87% |
| Sep 30, 22 | 2.11 M Increased by +180.85% | -21.17 M Increased by +9.50% | Decreased by -1.00 K% Increased by +67.78% |
| Jun 30, 22 | 1.39 M Increased by +N/A% | -22.27 M Increased by +5.58% | Decreased by -1.60 K% Decreased by N/A% |
| Mar 31, 22 | 813.00 K Increased by +251.95% | -23.48 M Increased by +3.98% | Decreased by -2.89 K% Increased by +72.72% |